Historical review from 2026-09-12. Current price and availability are unconfirmed; check the original marketplace.
Insect Bite ID shows $2.7K/mo revenue with an extraordinary 99.9% profit margin and a 2.3x annual profit multiple—both attractive on paper. However, the implausibly high margin (nearly 100% net profit) and lack of disclosed customer count, retention data, growth trajectory, and acquisition-channel transparency raise material questions about sustainability and business durability. Platform verification is confirmed, which is a strength, but the buyer should independently validate the margin claim and understand how this early-stage AI application acquires and retains paying users before committing.
The core software—a photo-upload UI, AI image classification API integration (via OpenAI Vision or similar), bite identification logic, and simple tracking database—is reproducible in 6 weeks for $3–8K using AI coding tools, Supabase/Firebase, and existing vision APIs. What you would not acquire is paying customer traction, retention proof, or a validated acquisition channel. At $2.7K/mo with unconfirmed durability, retention, and customer concentration, the business traction does not yet justify the $75K acquisition cost over rebuilding independently and owning customer acquisition from day one. If customer count is high (100+), churn is <5% monthly, and growth is >10% MoM, the verdict shifts to BUY; current evidence does not support that confidence.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Snap a photo to identify insect bites in seconds with AI. Get confidence scores, bite care advice, and track bites over time for extra peace of mind.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.